Conventional DMARDs (disease modifying antirheumatic drugs), such as include sulfazalazine, Plaquenil and methotrexate, affect RA processes to slow down the disease. The Biologic DMARDs were introduced in 2000. Engineered to inhibit responses involved in RA, the Biologics include infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), certolizumab (Cimzia), golimumab (Simponi), tociluzimab (Actemra), and abatacept(Orencia). The Biologic DMARDs are given through IV infusion or injection. Small molecule therapies, including tofacitinib (Xeljanz), can be used for RA and are available in tablet form.